DOCSLIB.ORG

RECEPTOR ANTAGONISTS Vasopressin V2 Receptor Antagonists

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
RECEPTOR ANTAGONISTS Vasopressin V2 Receptor Antagonists 1 RECEPTOR ANTAGONISTS Vasopressin V2 receptor antagonists J G Verbalis 232 Building D, Division of Endocrinology and Metabolism, Georgetown University School of Medicine, 4000 Reservoir Road NW, Washington DC 20007, USA (Requests for offprints should be addressed toJGVerbalis; Email: [email protected]) Abstract Hyponatremia, whether due to the syndrome of inappropriate antidiuretic hormone secretion (SIADH) or disorders of water retention such as congestive heart failure and cirrhosis, is a very common problem encountered in the care of medical patients. To date, available treatment modalities for disorders of excess arginine vasopressin (AVP) secretion or action have been limited and suboptimal. The recent discovery and development of nonpeptide AVP V2 receptor antagonists represents a promising new treatment option to directly antagonize the effects of elevated plasma AVP concentrations at the level of the renal collecting ducts. By decreasing the water permeability of renal collecting tubules, excretion of retained water is promoted, thereby normalizing or improving hypo-osmolar hyponatremia. In this review, SIADH and other water retaining disorders are briefly discussed, after which the published preclinical and clinical studies of several nonpeptide AVP V2 receptor antagonists are summarized. The likely therapeutic indications and potential complications of these compounds are also described. Journal of Molecular Endocrinology (2002) 29, 1–9 Introduction heart failure (CHF) and cirrhosis with ascites. In these disorders, a relatively decreased intravascular Arginine vasopressin (AVP), the ‘antidiuretic volume and/or pressure leads to water retention as a hormone,’ is the major physiological regulator of result of both decreased distal delivery of glomerular renal free water excretion. Increased AVP secretion filtrate and secondarily elevated plasma AVP levels. causes an antidiuresis, with subsequent retention of For example, hyponatremic patients with advanced water by the kidney. Disorders of AVP secretion congestive heart failure often have inappropriately cause imbalances of body water. The most elevated plasma AVP levels, which fail to sup- prominent of these is the syndrome of inappropri- press completely even after acute water loading ate antidiuretic hormone secretion (SIADH). (Goldsmith et al. 1986). This occurs because low Patients with SIADH fail to suppress AVP secretion cardiac output causes an underfilling of the arterial even when the plasma osmolality falls below the vascular compartment, which unloads barorecep- normal osmotic threshold for stimulating AVP tors thereby activating the renin–angiotensin– secretion (Zerbe et al. 1980). Total body water aldosterone system, the sympathetic nervous system increases as a result of the impaired renal water and AVP secretion in an effort to increase vascular excretion, causing dilutional hypo-osmolality and resistance and enhance renal Na+ and water reten- hyponatremia (Verbalis 2001). The clinical criteria tion. Similar mechanisms occur in patients with required for a diagnosis of SIADH remain basically advanced cirrhosis and ascites with edema (Bichet the same as when the syndrome was first described et al. 1982); despite a generalized hypervolemic by Bartter and Schwartz in 1967. edematous state, there is avid renal Na+ and water Hypo-osmolar hyponatremia also occurs rela- retention in an attempt to maintain the effective tively frequently in advanced stages of congestive arterial blood volume (Schrier 1988). Journal of Molecular Endocrinology (2002) 29, 1–9 Online version via http://www.endocrinology.org 0952–5041/02/029–001 © 2002 Society for Endocrinology Printed in Great Britain Downloaded from Bioscientifica.com at 09/28/2021 08:49:37PM via free access 2 J G VERBALIS · Vasopressin V2 receptor antagonists Treatment strategies: disorders of at the V2 receptors in the collecting ducts of the hormone excess kidney. These agents, therefore, have the potential to increase free water excretion during states of Because SIADH is a disorder of relative AVP AVP excess, regardless of the cause of the AVP excess, it is rational to attempt to apply therapeutic hypersecretion. strategies similar to those used for other endocrine disorders of hormone excess. These include: (1) decreasing the secretion of the hormone, (2) AVP receptor subtypes decreasing the effects of the hormone at its target tissues, and (3) compensating for the effects All AVP receptor subtypes belong to the seven produced by the excess hormone secretion. transmembrane domain, G-protein-coupled recep- Although several drugs have been described that tor superfamily. Three known receptor subtypes decrease AVP secretion in some cases (e.g. ethanol, mediate all of the known actions of AVP; they are diphenylhydantoin, opiates), responses are erratic classified according to the second messenger system and often unpredictable. The second approach to to which they are coupled (Thibonnier et al. 1998). treating hormone hypersecretion, namely antago- The V1a and V1b (also known as V3) receptors are nizing the end-organ effects of the hormone, has linked to the phosphoinositol signaling pathway met with limited success. Until recently, pharmaco- with intracellular calcium acting as the second logical intervention for SIADH has been restricted messenger. In contrast, the V2 receptors are linked to drugs with predominantly post-receptor effects. to the adenylate cyclase signaling pathway with The tetracycline derivative, demeclocycline, causes intracellular cAMP acting as the second messenger. a nephrogenic form of diabetes insipidus, decreas- The V1a receptor subtype is ubiquitous and is ing urine concentration even in the presence of present on vascular smooth muscle cells, hepato- high AVP levels (Dousa & Wilson 1974). However, cytes and platelets where it mediates vascular demeclocycline can cause nephrotoxicity, especially constriction, glycogenolysis and platelet aggrega- in patients with cirrhosis, although in most cases tion respectively. V1b,orV3, receptors are found this has been reversible. Other agents, such as predominantly in the anterior pituitary where they lithium carbonate, have similar post-receptor mediate adrenocorticotropin release. V2 receptors effects but are less desirable because of inconsistent are present predominantly in the kidney collecting results and significant side effects. Because of the tubules where they mediate free water reabsorp- multiple problems associated with these therapies, tion. In addition, there is now evidence indicating the most frequently employed strategy in SIADH the presence of extrarenal V2 receptors, such as has been to attempt to compensate for the effects of those involved in von Willebrand factor secretion excess AVP secretion by restricting free water (Bernat et al. 1997). Activation of the V2 receptor in intake. Reduction of fluid intake to levels less than renal collecting ducts by circulating AVP leads to insensible losses plus kidney free water excretion an increase in intracellular cAMP by stimulating induces a negative water balance, with subsequent adenylate cyclase activity through Gs protein. This, increases in plasma osmolality and serum [Na+]. in turn, regulates renal free water excretion by Although fluid restriction can effectively counteract shuttling aquaporin-2 (AQP2) water channels from the effect of excess AVP secretion, it does not intracellular vesicles into the apical plasma directly inhibit excess hormone secretion, nor its membrane of the renal collecting duct cells, actions in the kidney. Furthermore, for many thereby increasing water permeability of the patients, long-term fluid restriction can be uncom- membrane and producing an antidiuresis (Nielsen fortable, difficult to maintain, and relatively et al. 1999). ineffective. With the cloning and sequencing of the receptors to which AVP binds, agents that can more directly AVP receptor antagonists antagonize the effects of the hormone at its receptors have now been synthesized. By virtue of Manning and Sawyer first designed peptide these actions, AVP V2 receptor antagonists are antagonists of both the antidiuretic and the promising agents that can block the actions of AVP pressor responses to AVP in the 1970s. Starting Journal of Molecular Endocrinology (2002) 29, 1–9 www.endocrinology.org Downloaded from Bioscientifica.com at 09/28/2021 08:49:37PM via free access Vasopressin V2 receptor antagonists · J G VERBALIS 3 by modifying the highly specific and potent showed a relative V2:V1 selectivity of over antidiuretic peptide desmopressin, a selective 7000-fold in rat and 100-fold in human tissues. peptide V2 receptor agonist, they successfully SR-121463 also potently antagonized AVP- synthesized many vasopressin analogs that effec- stimulated adenylyl cylase activity. VPA-985, tively antagonized the antidiuretic response of AVP another potent selective nonpeptide V2 receptor in vivo (Manning & Sawyer 1991). However, despite antagonist, similarly inhibited binding of AVP to demonstrating potent V2 receptor antagonism in native V2 receptors in membrane isolates from rat animals, many V2 receptor antagonists tested in and dog renal medulla (Chan et al. 1998). In 1997, humans have paradoxically exhibited weak V2 Tahara et al. characterized a nonpeptide combined receptor agonism rather than antagonizing the V1a and V2 receptor antagonist, YM-087. This ff ffi antidiuretic e ects of AVP. Subsequent studies agent demonstrated a high a nity for V1a ff have suggested that this marked species di erence receptors
Load more

Recommended publications
  • Antibiotic Assay Medium No. 3 (Assay Broth) Is Used for Microbiological Assay of Antibiotics. M042
    HiMedia Laboratories Technical Data Antibiotic Assay Medium No. 3 (Assay Broth) is used for M042 microbiological assay of antibiotics. Antibiotic Assay Medium No. 3 (Assay Broth) is used for microbiological assay of antibiotics. Composition** Ingredients Gms / Litre Peptic digest of animal tissue (Peptone) 5.000 Beef extract 1.500 Yeast extract 1.500 Dextrose 1.000 Sodium chloride 3.500 Dipotassium phosphate 3.680 Potassium dihydrogen phosphate 1.320 Final pH ( at 25°C) 7.0±0.2 **Formula adjusted, standardized to suit performance parameters Directions Suspend 17.5 grams in 1000 ml distilled water. Heat if necessary to dissolve the medium completely. Sterilize by autoclaving at 15 lbs pressure (121°C) for 15 minutes. Advice:Recommended for the Microbiological assay of Amikacin, Bacitracin, Capreomycin, Chlortetracycline,Chloramphenicol,Cycloserine,Demeclocycline,Dihydrostreptomycin, Doxycycline, Gentamicin, Gramicidin, Kanamycin, Methacycline, Neomycin, Novobiocin, Oxytetracycline, Rolitetracycline, Streptomycin, Tetracycline, Tobramycin, Trolendomycin and Tylosin according to official methods . Principle And Interpretation Antibiotic Assay Medium is used in the performance of antibiotic assays. Grove and Randall have elucidated those antibiotic assays and media in their comprehensive treatise on antibiotic assays (1). Antibiotic Assay Medium No. 3 (Assay Broth) is used in the microbiological assay of different antibiotics in pharmaceutical and food products by the turbidimetric method. Ripperre et al reported that turbidimetric methods for determining the potency of antibiotics are inherently more accurate and more precise than agar diffusion procedures (2). Turbidimetric antibiotic assay is based on the change or inhibition of growth of a test microorganims in a liquid medium containing a uniform concentration of an antibiotic. After incubation of the test organism in the working dilutions of the antibiotics, the amount of growth is determined by measuring the light transmittance using spectrophotometer.
    [Show full text]
  • Antibacterial Residue Excretion Via Urine As an Indicator for Therapeutical Treatment Choice and Farm Waste Treatment
    antibiotics Article Antibacterial Residue Excretion via Urine as an Indicator for Therapeutical Treatment Choice and Farm Waste Treatment María Jesús Serrano 1, Diego García-Gonzalo 1 , Eunate Abilleira 2, Janire Elorduy 2, Olga Mitjana 1 , María Victoria Falceto 1, Alicia Laborda 1, Cristina Bonastre 1 , Luis Mata 3 , Santiago Condón 1 and Rafael Pagán 1,* 1 Instituto Agroalimentario de Aragón-IA2, Universidad de Zaragoza-CITA, 50013 Zaragoza, Spain; [email protected] (M.J.S.); [email protected] (D.G.-G.); [email protected] (O.M.); [email protected] (M.V.F.); [email protected] (A.L.); [email protected] (C.B.); [email protected] (S.C.) 2 Public Health Laboratory, Office of Public Health and Addictions, Ministry of Health of the Basque Government, 48160 Derio, Spain; [email protected] (E.A.); [email protected] (J.E.) 3 Department of R&D, ZEULAB S.L., 50197 Zaragoza, Spain; [email protected] * Correspondence: [email protected]; Tel.: +34-9-7676-2675 Abstract: Many of the infectious diseases that affect livestock have bacteria as etiological agents. Thus, therapy is based on antimicrobials that leave the animal’s tissues mainly via urine, reaching the environment through slurry and waste water. Once there, antimicrobial residues may lead to antibacterial resistance as well as toxicity for plants, animals, or humans. Hence, the objective was to describe the rate of antimicrobial excretion in urine in order to select the most appropriate molecule while reducing harmful effects. Thus, 62 pigs were treated with sulfamethoxypyridazine, Citation: Serrano, M.J.; oxytetracycline, and enrofloxacin. Urine was collected through the withdrawal period and analysed García-Gonzalo, D.; Abilleira, E.; via LC-MS/MS.
    [Show full text]
  • Demeclocycline
    PATIENT & CAREGIVER EDUCATION Demeclocycline This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. What is this drug used for? It is used to treat bacterial infections. It may be given to you for other reasons. Talk with the doctor. What do I need to tell my doctor BEFORE I take this drug? If you have an allergy to demeclocycline or any other part of this drug. If you are allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had. If you are taking penicillin. If you are breast-feeding or plan to breast-feed. This is not a list of all drugs or health problems that interact with this drug. Tell your doctor and pharmacist about all of your drugs Demeclocycline 1/8 (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take this drug with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor. What are some things I need to know or do while I take this drug? Tell all of your health care providers that you take this drug. This includes your doctors, nurses, pharmacists, and dentists. Avoid driving and doing other tasks or actions that call for you to be alert until you see how this drug affects you.
    [Show full text]
  • TETRACYCLINES and CHLORAMPHENICOL Protein Synthesis
    ANTIMICROBIALS INHIBITING PROTEIN SYNTHESIS AMINOGLYCOSIDES MACROLIDES TETRACYCLINES AND CHLORAMPHENICOL Protein synthesis Aminoglycosides 1. Aminoglycosides are group of natural and semi -synthetic antibiotics. They have polybasic amino groups linked glycosidically to two or more aminosugar like: sterptidine, 2-deoxy streptamine, glucosamine 2. Aminoglycosides which are derived from: Streptomyces genus are named with the suffix –mycin. While those which are derived from Micromonospora are named with the suffix –micin. Classification of Aminoglycosides 1. Systemic aminogycosides Streptomycin (Streptomyces griseus) Gentamicin (Micromonospora purpurea) Kanamycin (S. kanamyceticus) Tobramycin (S. tenebrarius) Amikacin (Semisynthetic derivative of Kanamycin) Sisomicin (Micromonospora inyoensis) Netilmicin (Semisynthetic derivative of Sisomicin) 2. Topical aminoglycosides Neomycin (S. fradiae) Framycetin (S. lavendulae) Pharmacology of Streptomycin NH H2N NH HO OH Streptidine OH NH H2N O O NH CHO L-Streptose CH3 OH O HO O HO NHCH3 N-Methyl-L- Glucosamine OH Streptomycin Biological Source It is a oldest aminoglycoside antibiotic obtained from Streptomyces griseus. Antibacterial spectrum 1. It is mostly active against gram negative bacteria like H. ducreyi, Brucella, Yersinia pestis, Francisella tularensis, Nocardia,etc. 2. It is also used against M.tuberculosis 3. Few strains of E.coli, V. cholerae, H. influenzae , Enterococci etc. are sensitive at higher concentration. Mechanism of action Aminoglycosides bind to the 16S rRNA of the 30S subunit and inhibit protein synthesis. 1. Transport of aminoglycoside through cell wall and cytoplasmic membrane. a) Diffuse across cell wall of gram negative bacteria by porin channels. b) Transport across cell membrane by carrier mediated process liked with electron transport chain 2. Binding to ribosome resulting in inhibition of protein synthesis A.
    [Show full text]
  • Demeclocycline in the Treatment of the Syndrome of Inappropriate Secretion of Antidiuretic Hormone
    Thorax: first published as 10.1136/thx.34.3.324 on 1 June 1979. Downloaded from Thorax, 1979, 34, 324-327 Demeclocycline in the treatment of the syndrome of inappropriate secretion of antidiuretic hormone W H PERKS, E H WALTERS,' I P TAMS, AND K PROWSE From the Department of Respiratory Physiology, City General Hospital, Stoke-on-Trent, Staffordshire, UK ABSTRACT Fourteen patients with the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) have been treated with demethylchlortetracycline (demeclocycline) 1200 mg daily. In 12 patients the underlying lesion was malignant. The serum sodium returned to normal (> 135 mmol/l) in all patients after a mean of 8-6 days (SD+5-3 days). Blood urea rose significantly from the pretreatment level of 4-2±2-3 mmol/l to 10-1±5-1 mmol/l at ten days (p<0 001). The average maximum blood urea was 13-4-6-8 mmol/l. In four patients the urea rose above 20 mmol/l, and in two of these demecyocycline was discontinued because of this rise. The azotaemia could be attributed to a combination of increased urea production and a mild specific drug-induced nephrotoxicity. Discontinuation of demeclocycline in six patients led to a fall in serum sodium, in one case precipitously, and return of the urea towards normal levels. Demeclocycline appears therefore to be an effective maintenance treatment of SIADH, and the azotaemia that occurs is reversible and probably dose dependent. The syndrome of inappropriate secretion of anti- Methods http://thorax.bmj.com/ diuretic hormone (SIADH) has become increas- ingly recognised as a treatable cause of stupor and Fourteen patients with a diagnosis of SIADH confusion in patients with a wide variety of based on the criteria of De Troyer and Demanet diseases (De Troyer and Demanet, 1976).
    [Show full text]
  • The Current Art of Diuretic Therapy for Heart Failure: a Personal Viewpoint
    Journal of Cardiology & Current Research Review Article Open Access The current art of diuretic therapy for heart failure: a personal viewpoint Abstract Volume 11 Issue 2 - 2018 Diuretic therapy for heart failure is not that simple. There are nowadays several diuretics and natriuretics, with potential interactions, and different doses and ways of Ezequiel J Zaidel use. Furosemide plays a key role in the treatment of acute decompensated heart failure Department of Pharmacology, School of Medicine, University of and chronic heart failure. Buenos Aires, and Cardiology Department-Heart Failure Unit, Sanatorio Güemes University Hospital, Argentina Keywords: Diuretics, furosemide, heart failure Correspondence: Ezequiel J Zaidel, Department of Pharmacology, School of Medicine, University of Buenos Aires, and Cardiology Department-heart failure unit, Sanatorio Güemes University Hospital, Paraguay 2155 (zip 1121), 15th Floor M1, Buenos Aires, Argentina, Tel +54 11 59509500, int 2205, Email [email protected] Received: March 19, 2018 | Published: March 29, 2018 Introduction intestine wall. This factor, associated with the delayed onset of action, favors other routes of administration. Most of the times, intravenous Heart Failure is nowadays epidemic, being the main cause of furosemide is used, but the timing for downgrading to oral use is 1 hospitalization in adults. There are several classifications, but there not exactly known and it may lead to therapeutic failure and early is a great distinction in two syndromes, acute decompensated heart readmissions. The intramuscular administration leads to erratic failure (ADHF), and chronic heart failure, in patients who daily drug concentration and effects, and currently there are other ways deal with congestion and frequent titration of diuretics (CHF).
    [Show full text]
  • Analysis of Tetracyclines in Medicated Feed for Food Animal Production by HPLC-MS/MS
    Article Analysis of Tetracyclines in Medicated Feed for Food Animal Production by HPLC-MS/MS Rosa Elvira Gavilán 1,†, Carolina Nebot 1,†,*, Jose Manuel Miranda 1,†, Yolanda Martín-Gómez 2,†, Beatriz Vázquez-Belda 1,†, Carlos Manuel Franco 1,† and Alberto Cepeda 1,† Received: 31 July 2015; Accepted: 15 December 2015; Published: 24 December 2015 Academic Editor: Christopher C. Butler 1 Department of Analytical Chemistry, Nutrition and Bromatology, Faculty of Veterinary Medicine, University of Santiago de Compostela, 27002 Lugo, Spain; [email protected] (R.E.G.); [email protected] (J.M.M.); [email protected] (B.V.-B.); [email protected] (C.M.F.); [email protected] (A.C.) 2 Laboratorio de Sanidad Animal, Lugar Barrio Jove de Arriba, 0 S/N, 33290 Gijón, Spain; [email protected] * Correspondence: [email protected]; Tel.: +34-982-822-454; Fax: +34-982-254-592 † These authors contributed equally to this work. Abstract: The use of medicated feed is a common practice in animal food production to improve animal health. Tetracyclines and β-Lactams are the groups that are most frequently added to this type of feed. The measurement of the concentration of the analytes in these types of samples is sometimes due to the matrix characteristic, and manufacturers are demanding fast, precise and reproducible methods. A rapid confirmatory method based on a simple extraction protocol using acidified methanol and followed by high performance liquid chromatography coupled to a tandem mass spectrometer for the quantification of four tetracyclines in feed is presented. Validation was performed following the guidelines of Decision 2002/657/EC.
    [Show full text]
  • Tetracyclines and Chloramphenicol
    CHAPTER 29 Tetracyclines and Chloramphenicol AT A GLANCE Tetracyclines Pseudotumur Cerebri Antimicrobial Spectrum Drug Interactions of Tetracyclines Mechanism of Action (Fig. 29.2) Chloramphenicol Bacterial Resistance Antimicrobial Spectrum Pharmacokinetics Mechanism of Action Classification of Tetracyclines Bacterial Resistance Clinical Uses of Tetracyclines Pharmacokinetics H. pylori Infection Clinical Uses Tigecycline Adverse Effects Adverse Effects of Tetracyclines Drug Interactions The antimicrobial agents that act by inhibiting bacterial OH O OH O protein synthesis are bacteriostatic in their action and OH3 O 10 11 1 12 C include agents such as tetracyclines, chloramphenicol, 9 2 NH macrolides, ketolides, clinda mycin, quinupristin/ 2 dalfopristine, linezolid and spectinomycin. Though 8 3 7 6 5 4 they can be broadly referred to as protein synthesis inhibitors, they have different target sites to elicit their R7 R6 OH HR5 H N(CH32) action. Thus, they can act on 30S or 50S ribosomal R R R subunits to inhibit bacterial protein synthesis and act 7 6 5 as bacteriostatic agents. Chlortetracyline —Cl —CH3 —H Oxytetracycline —H —CH —OH Tetracycline —H 3 —H Demethylchlortetracycline —CH3 —H TETRACYCLINES (Demeclocycline) —Cl —H —OH —OH Methacycline —H —CH2 Doxycycline —H —H Tetracyclines are a class of broad-spectrum antibiotics —CH3 Minocycline — N(CH ) that are used in a wide variety of microbial diseases. In 32 —H 1947, in his study of thousands of microscopic fungi Fig. 29.1 Structural formulae of tetracyclines amongst the Actinomycetes, Duggar in collaboration with discovered a soil Yellapragada Subba Rao Antimicrobial Spectrum organism for which the name Streptomyces29.1 aureofaciens was proposed. When grown in culture broth, a golden Tetracyclines are broad-spectrum antibiotics and yellow antibiotic was elaborated that was named are effective against Gram-positive, Gram-negative Aureomycin (chlortetracycline).
    [Show full text]
  • Diabetes Insipidus: Diagnosis and Treatment of a Complex Disease
    REVIEW AMGAD N. MAKARYUS, MD SAMY I. McFARLANE, MD, MPH CME North Shore University Hospital, New York University State University of New York-Downstate and Kings CREDIT School of Medicine, Manhasset, NY County Hospital Center, Brooklyn, NY Diabetes insipidus: Diagnosis and treatment of a complex disease ■ ABSTRACT ATIENTS WHO PRESENT with diabetes P insipidus need immediate care because Diabetes insipidus, characterized by excretion of copious the body’s delicate water and electrolyte bal- volumes of dilute urine, can be life-threatening if not ance is threatened. It is essential to perform a properly diagnosed and managed. It can be caused by knowledgeable assessment based on character- two fundamentally different defects: inadequate or izing features, intervene rapidly with the prop- impaired secretion of antidiuretic hormone (ADH) from er treatment, and continue to reevaluate the the posterior pituitary gland (neurogenic or central patient’s condition. diabetes insipidus) or impaired or insufficient renal Complicating matters, the proper treat- response to ADH (nephrogenic diabetes insipidus). The ment depends on the cause in the individual distinction is essential for effective treatment. patient. Therefore, the physician must deter- mine whether the defect is in the brain or in ■ KEY POINTS the kidney. ■ Urine osmolality is easy to measure and helps in INABILITY TO CONSERVE WATER determining whether polyuria is due to diabetes insipidus or another condition. Diabetes insipidus is caused by the inability to conserve water and maintain an optimum free water level. The kidneys pass large The water deprivation test can help in distinguishing amounts of dilute urine regardless of the central diabetes insipidus from nephrogenic diabetes body’s hydration state, leading to symptoms of insipidus.
    [Show full text]
  • Current and Future Treatment Options in SIADH
    NDT Plus (2009) 2 [Suppl 3]: iii12–iii19 doi: 10.1093/ndtplus/sfp154 Current and future treatment options in SIADH Robert Zietse, Nils van der Lubbe and Ewout J. Hoorn Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands Correspondence and offprint requests to: Robert Zietse; E-mail: [email protected] Abstract long-term treatment may be necessary. Although there are The treatment of hyponatraemia due to SIADH is not always several approaches to the treatment of SIADH, none of the as straightforward as it seems. Although acute treatment present treatment options is without problems [3]. with hypertonic saline and chronic treatment with fluid re- Before delving into specific forms of treatment, one striction are well established, both approaches have severe should consider the question: ‘Are all patients with SIADH limitations. These limitations are not readily overcome by alike?’ Although vasopressin levels appear largely indepen- addition of furosemide, demeclocycline, lithium or urea dent of serum osmolality in roughly one third of the patients, to the therapy. In theory, vasopressin-receptor antagonists many patients exhibit some form of vasopressin responsive- would provide a more effective method to treat hypona- ness albeit at a lower serum osmolality [2]. In such cases, traemia, by virtue of their ability to selectively increase excessive fluid intake appears equally important to vaso- solute-free water excretion by the kidneys (aquaresis). In pressin release in the initiation of hyponatraemia. This may this review we explore the limitations of the current treat- be due to regulation at a lower setpoint (i.e. a ‘reset os- ment of SIADH and describe emerging therapies for the mostat’) [2].
    [Show full text]
  • Demeclocycline Hydrochloride Tablets, Usp for Oral Use Rx Only
    DEMECLOCYCLINE HYDROCHLORIDE TABLETS, USP FOR ORAL USE RX ONLY To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION Demeclocycline hydrochloride is an antibiotic isolated from a mutant strain of Streptomyces aureofaciens. Chemically it is 7-Chloro-4-(dimethylamino)­ 1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-2­ naphthacenecarboxamide monohydrochloride. Its structural formula is: Demeclocycline hydrochloride tablets, USP, for oral administration, contain 150 mg or 300 mg of demeclocycline hydrochloride and the following inactive ingredients: alginic acid, corn starch, D&C Red #7, D&C Yellow #10 Aluminium Lake, ethylcellulose, hypromellose, light mineral oil, magnesium stearate, mineral oil, sodium lauryl sulfate, sorbitol and titanium dioxide. CLINICAL PHARMACOLOGY Pharmacokinetics The absorption of demeclocycline is slower than that of tetracycline. The time to reach the peak concentration is about 4 hours. After a 150 mg oral dose of demeclocycline tablet, the mean concentrations at 1 hour and 3 hours are 0.46 and 1.22 µg/mL (n=6) respectively. The serum half-life ranges between 10 and 16 hours. When demeclocycline hydrochloride is given concomitantly with some dairy products, or antacids containing aluminum, calcium, or magnesium, the extent of absorption is reduced by more than 50%. Demeclocycline hydrochloride penetrates well into various body fluids and tissues. The percent of demeclocycline hydrochloride bound to plasma protein is about 40% using a dialysis equilibrium method and 90% using an ultra-filtration method.
    [Show full text]
  • Clinical Commissioning Policy: Tolvaptan for Hyponatraemia
    Clinical Commissioning Policy: Tolvaptan for hyponatraemia secondary to the Syndrome of Inappropriate Antidiuretic Hormone (SIADH) in patients requiring cancer chemotherapy Reference: NHS England: 16051/P OFFICIAL NHS England INFORMATION READER BOX Directorate Medical Operations and Information Specialised Commissioning Nursing Trans. & Corp. Ops. Commissioning Strategy Finance Publications Gateway Reference: 05527s Document Purpose Policy Tolvaptan for hyponatraemia secondary to the Syndrome of Document Name Inappropriate Antidiuretic Hormone (SIADH) in patients requiring cancer chemotherapy Author Specialised Commissioning Team Publication Date 12 December 2016 Target Audience CCG Clinical Leaders, Care Trust CEs, Foundation Trust CEs , Medical Directors, Directors of PH, Directors of Nursing, NHS England Regional Directors, NHS England Directors of Commissioning Operations, Directors of Finance, NHS Trust CEs Additional Circulation #VALUE! List Description Routinely Commissioned - NHS England will routinely commission this specialised treatment in accordance with the criteria described in this policy. Cross Reference N/A Superseded Docs N/A (if applicable) Action Required N/A Timing / Deadlines N/A (if applicable) Contact Details for [email protected] further information 0 0 Document Status This is a controlled document. Whilst this document may be printed, the electronic version posted on the intranet is the controlled copy. Any printed copies of this document are not controlled. As a controlled document, this document should not be saved onto local or network drives but should always be accessed from the intranet. 2 OFFICIAL Standard Operating Procedure: Clinical Commissioning Policy: Tolvaptan for hyponatraemia secondary to the Syndrome of Inappropriate Antidiuretic Hormone (SIADH) in patients requiring cancer chemotherapy First published: December 2016 Prepared by NHS England Specialised Services Clinical Reference Group for Specialised Endocrinology Published by NHS England, in electronic format only.
    [Show full text]